Citations 1
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
Garzon, Ramiro , Volinia, Stefano , Papaioannou, Dimitrios , Kohlschmidt, Jessica, Yan, Pearlly S. , Mrózek, Krzysztof , Bucci, Donna, Carroll, Andrew J. , Baer, Maria R. , Wetzler, Meir , Carter, Thomas H. , Powell, Bayard L., Kolitz, Jonathan E. , Moore, Joseph O., Eisfeld, Ann-Kathrin, Blachly, James S. , Blum, William , Stone, Richard M. , Marcucci, Guido , Byrd, John C. , Bloomfield, Clara D. , Byrd, John C. , Nicolet, Deedra , Eisfeld, Ann‐Kathrin , Caligiuri, Michael A. , Croce, Carlo Maria , Blachly, James , Byrd, John C
Proceedings of the National Academy of Sciences | December 15, 2014 | Volume: 111 | Issue: 52 | Pages: 18679-18684
Significance Long noncoding RNAs (lncRNAs) are involved in numerous biological roles including epigenetic regulation, apoptosis, and cell cycle. Whereas lncRNAs contribute to epigenetic gene regulation, metastasis, and prognosis in solid tumors, their role in acute myeloid leukemia (AML) has not been hitherto reported. Here, we show that lncRNA expression profiles are associated with recurrent mutations, clinical features, and outcome in AML. A fraction of these lncRNAs may have a functional role in leukemogenesis. Furthermore, lncRNAs could be used as biomarkers for outcome in AML. The identification of patients likely to achieve complete remission with standard therapy alone, based on lncRNA expression, is a significant advance potentially sparing such patients from other toxicities and focusing investigational approaches on postremission studies.